Lucid Diligence Brief: EpilepsyGTx $33m Series A
Lucid Diligence Brief: EpilepsyGTx $33m Series A Professional audiences only.…
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B
Lucid Diligence Brief: SanegeneBio RNAi $110 million Series B Professional…
Lucid Diligence Brief: Mirum to acquire Bluejay Therapeutics
Lucid Diligence Brief: Mirum to acquire Bluejay Therapeutics Professional…
Lucid Diligence Brief: SciNeuro Pharmaceuticals $53M financing
Lucid Diligence Brief: SciNeuro Pharmaceuticals $53M financing Professional…
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer Ventures
Lucid Diligence Brief: OTR Therapeutics Series A $100 million backed by Pfizer…
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+ NSCLC
Lucid Diligence Brief: Triana Biomedicines $120M Series B for TRI-611 in ALK+…
Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research Business
Lucid Diligence Brief: Paradigm to acquire Flatiron’s Clinical Research…
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy for lung cancer
Lucid Diligence Brief: CorriXR × InhaTarget × Merxin, inhaled CRISPR therapy…
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA biomarkers
Lucid Diligence Brief: Circular Genomics $15 million Series A for circular RNA…
Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD
Lucid Diligence Brief: Regeneron and Tessera team on TSRA-196 for AATD…
Lucid Diligence Brief: Protego Biopharma $130M Series B
Lucid Diligence Brief: Protego Biopharma $130M Series B Professional audiences…
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen collaboration
Lucid Diligence Brief: Dayra Therapeutics, Versant Ventures and Biogen…